stoxline Quote Chart Rank Option Currency Glossary
Vaccinex, Inc. (VCNX)
0.653  -0.046 (-6.58%)    12-07 15:59
Open: 0.7
High: 0.7237
Volume: 56,786
Pre. Close: 0.699
Low: 0.651
Market Cap: 8(M)
Technical analysis
2023-12-07 4:24:03 PM
Short term     
Mid term     
Targets 6-month :  0.95 1-year :  1.12
Resists First :  0.81 Second :  0.95
Pivot price 0.8
Supports First :  0.58 Second :  0.48
MAs MA(5) :  0.68 MA(20) :  0.82
MA(100) :  2.15 MA(250) :  5.11
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  30.7 D(3) :  30.8
RSI RSI(14): 33.6
52-week High :  12.3 Low :  0.58
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VCNX ] has closed above bottom band by 20.5%. Bollinger Bands are 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.73 - 0.73 0.73 - 0.73
Low: 0.64 - 0.65 0.65 - 0.65
Close: 0.68 - 0.69 0.69 - 0.7
Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Headline News

Mon, 04 Dec 2023
Vaccinex says Nasdaq gives co extension to regain compliance with listing rule - Seeking Alpha

Mon, 04 Dec 2023
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule - GlobeNewswire

Thu, 26 Oct 2023
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in ... - Yahoo Finance

Fri, 13 Oct 2023
Should You Accumulate Vaccinex Inc (VCNX) Stock Friday Morning? - InvestorsObserver

Fri, 06 Oct 2023
Should You Sell Vaccinex Inc (VCNX) Stock Friday Morning? - InvestorsObserver

Fri, 06 Oct 2023
Why Is Vaccinex (VCNX) Stock Up 26% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out -11 (M)
Shares Float 0 (M)
Held by Insiders 1.249e+007 (%)
Held by Institutions 4.88e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.37e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -5.99
Profit Margin 0 %
Operating Margin -29 %
Return on Assets (ttm) 170 %
Return on Equity (ttm) -257.6 %
Qtrly Rev. Growth 797.6 %
Gross Profit (p.s.) 0
Sales Per Share -364.54
EBITDA (p.s.) -1.20175e+007
Qtrly Earnings Growth -2.288e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.12
Price to Sales -0.01
Price to Cash Flow 0
Stock Dividends
Dividend 50440
Forward Dividend 197960
Dividend Yield 7320750%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android